Antitumor Activity of Rivoceranib Against Canine Mammary Gland Tumor Cell Lines.
Anticancer Res
; 39(10): 5483-5494, 2019 Oct.
Article
em En
| MEDLINE
| ID: mdl-31570442
ABSTRACT
BACKGROUND/AIM:
Canine mammary gland tumors (CMGTs) are the most common tumors in female dogs. Rivoceranib (also known as apatinib) is a novel anti-angiogenic tyrosine kinase inhibitor that selectively binds to vascular endothelial growth factor receptor-2 (VEGFR2). The aim of this study was to disclose the antitumor effects of rivoceranib on CMGT cell lines. MATERIALS ANDMETHODS:
The direct effects of rivoceranib on CMGT cells in vitro were analyzed by cell proliferation and migration assays. Cell-cycle distribution and apoptotic ratio were analyzed by flow cytometry. Expression levels of phosphorylated VEGFR2 were evaluated by western blot analysis.RESULTS:
Rivoceranib treatment significantly reduced the proliferation and migration of CMGT cells in a dose-dependent manner. Flow cytometry results revealed significant increases in G0/G1 phase arrest and apoptosis proportional to the drug concentration used. Rivoceranib reduced the level of phosphorylated VEGFR2.CONCLUSION:
We confirm that rivoceranib exerts antitumor effects on CMGT cells by inhibiting biological functions.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Piridinas
/
Neoplasias Mamárias Animais
/
Inibidores de Proteínas Quinases
/
Antineoplásicos
Limite:
Animals
Idioma:
En
Revista:
Anticancer Res
Ano de publicação:
2019
Tipo de documento:
Article